Skip to main content

Table 4 CTCAE grade ≥3 adverse events observed in more than 5% of patients

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

 

Platinum combination therapy (n = 24)

Docetaxel monotherapy (n = 61)

 

Grade 3

Grade 4

Total (%)

Grade 3

Grade 4

Total (%)

p value*

Leukocytopenia

8

2

10 (41.6)

30

9

39 (63.9)

0.06

Neutropenia

8

6

14 (58.3)

16

28

44 (72.1)

0.08

Anemia

3

0

3 (12.5)

2

0

2 (3.3)

0.12

Febrile neutropenia

2

0

2 (8.3)

6

0

6 (9.8)

0.82

Anorexia

1

0

1 (4.2)

5

0

5 (8.2)

0.49

Infection

1

0

1 (4.2)

3

0

3 (4.9)

0.88

  1. Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events version 3.0.
  2. *Fisher’s exact test.